Clinical Characteristics and Outcomes of Liver Transplantation Recipients With COVID-19 Pneumonia

Basit Öğe Kaydı
dc.authoridYilmaz, Sezai/0000-0002-8044-0297
dc.authoridKose, Adem/0000-0002-1853-1243
dc.authoridtoplu, sibel altunışık/0000-0002-2915-4666
dc.authoridYalçınsoy, Murat/0000-0003-3407-7359
dc.authorwosidYilmaz, Sezai/ABI-2323-2020
dc.authorwosidYAKUPOGULLARI, YUSUF/F-3966-2011
dc.authorwosidKose, Adem/AAD-1226-2020
dc.authorwosidtoplu, sibel altunışık/ABH-5816-2020
dc.authorwosidYalçınsoy, Murat/ABI-1421-2020
dc.contributor.authorKose, Adem
dc.contributor.authorToplu, Sibel Altunisik
dc.contributor.authorYalcinsoy, Murat
dc.contributor.authorYakupogullari, Yusuf
dc.contributor.authorOtlu, Baris
dc.contributor.authorOtan, Emrah
dc.contributor.authorAydin, Cemalettin
dc.date.accessioned2024-08-04T20:50:25Z
dc.date.available2024-08-04T20:50:25Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground. We aimed to evaluate the clinical characteristics and outcomes of mild-severe COVID-19 pneumonia cases in liver transplant (LT) recipients. Methods. Ten LT recipients diagnosed as having COVID-19 pneumonia in a 6-month period in our transplantation center were included. Demographic and medical data of the recipients were retrospectively collected; clinical courses, treatment responses, and outcomes were evaluated. Results. Ten LT recipients were male, had a median age of 57 years (min-max, 36-69 years; interquartile range [IQR], 13 years), and had right lobe from living donor LT performed in a median of 11 months (min-max, 1-72 months; IQR, 12 months). Five patients had severe pneumonia, and the remaining patients had mild/moderate pneumonia. The most frequent symptoms were fever (90%) and cough (70%). Favipiravir, enoxaparin sodium, and corticosteroid were initiated at the time of the diagnosis; immunosuppressive drug doses were reduced or discontinued in 3 cases. Lymphopenia median: 510/mL (min-max, 90-1400 mL; IQR, 610 mL), increased levels of C-reactive protein median: 4.72 (min-max, 0.31-23.4; IQR, 8.5), and ferritin median: 641 (min-max, 40 to >= 1650; IQR, 1108) were frequent. Four patients required antibacterial treatments because of emerging bacterial pneumonia and/or sepsis. All patients were hospitalized for a median of 10 days. One patient with sepsis died on the 26th day after intensive care unit admission, and the remaining 9 survived. No further complication was recorded for 1-month follow-up. Conclusions. Commencing favipiravir, enoxaparin sodium, and corticosteroid treatments; close follow-up of the developing complications; the temporary reduction or cessation of immunosuppression; a multidisciplinary approach; early awareness of the bacterial infections; and the initiation appropriate antibiotic treatments can contribute to success.en_US
dc.identifier.doi10.1016/j.transproceed.2021.06.027
dc.identifier.endpage2489en_US
dc.identifier.issn0041-1345
dc.identifier.issn1873-2623
dc.identifier.issue8en_US
dc.identifier.pmid34261580en_US
dc.identifier.scopus2-s2.0-85110435854en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2481en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2021.06.027
dc.identifier.urihttps://hdl.handle.net/11616/100048
dc.identifier.volume53en_US
dc.identifier.wosWOS:000707458800008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keywords]en_US
dc.titleClinical Characteristics and Outcomes of Liver Transplantation Recipients With COVID-19 Pneumoniaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu